The NCL Foundation has opened the Rare-to-Common Neurodegeneration Impact Prize, a €200,000 research award supporting collaborative projects that connect CLN3 Batten disease research with more common neurodegenerative or age-related disorder
Clinical trials test new treatments or care approaches to assess their safety and efficacy in people. In rare diseases, they are a critical step in turning research into real clinical benefits.
